BCMA antibodies and use of same to treat cancer and immunological disorders
AssigneeSeagen Inc.
InventorsDjango Sussman, Maureen Ryan, Lori Westendorf, Michael Feldhaus
Life of this patent
Estimating the term…
Abstract
The invention provides humanized antibodies that specifically bind to BCMA. The antibodies are useful for treatment and diagnoses of various cancers and immune disorders as well as detecting BCMA.
Claims66
An isolated antibody or a binding fragment thereof that binds to human B-cell maturation antigen (BCMA), wherein the antibody or binding fragment comprises a mature heavy chain variable region and a mature light chain variable region, wherein the mature heavy chain variable region comprises complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 60, 61 and 62, and the mature light chain variable region comprises CDRs comprising the amino acid sequences of SEQ ID NOs:90, 91 and 92.
A bispecific antibody or binding fragment thereof that binds to human B-cell maturation antigen (BCMA), wherein the bispecific antibody or binding fragment comprises a mature heavy chain variable region and a mature light chain variable region, wherein the mature heavy chain variable region comprises complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 60, 61 and 62, and the mature light chain variable region comprises CDRs comprising the amino acid sequences of SEQ ID NOs:90, 91 and 92.
An isolated antibody or a binding fragment thereof that binds to human B-cell maturation antigen (BCMA), wherein the antibody or binding fragment comprises a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:19.
A bispecific antibody or binding fragment thereof, wherein the bispecific antibody or binding fragment comprises a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:19 that bind to human B-cell maturation antigen (BCMA).
An isolated, monoclonal, immunoglobulin G1 (IgG1) antibody that binds to human B-cell maturation antigen (BCMA), wherein the antibody comprises a mature heavy chain variable region and a mature light chain variable region, wherein the mature heavy chain variable region comprises complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 60, 61 and 62, and the mature light chain variable region comprises CDRs comprising the amino acid sequences of SEQ ID NOs:90, 91 and 92.
An isolated, monoclonal, immunoglobulin G1 (IgG1) antibody that binds to human B-cell maturation antigen (BCMA), wherein the antibody comprises a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:19.
An isolated, monoclonal, non-fucosylated antibody that binds to human B-cell maturation antigen (BCMA), wherein the antibody comprises a mature heavy chain variable region and a mature light chain variable region, wherein the mature heavy chain variable region comprises complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 60, 61 and 62, and the mature light chain variable region comprises CDRs comprising the amino acid sequences of SEQ ID NOs:90, 91 and 92.
An isolated, monoclonal, non-fucosylated antibody that binds to human B-cell maturation antigen (BCMA), wherein the antibody comprises a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:19.
A composition comprising a plurality of antibodies or binding fragments thereof that bind to human B-cell maturation antigen (BCMA), wherein
- (a) the antibodies or binding fragments comprise a mature heavy chain variable region and a mature light chain variable region, wherein the mature heavy chain variable region comprises complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 60, 61 and 62, and the mature light chain variable region comprises CDRs comprising the amino acid sequences of SEQ ID NOs:90, 91 and 92;
- and
- (b) less than 10% of the antibodies in the composition are fucosylated.
A composition comprising a plurality of antibodies or binding fragments thereof that bind to human B-cell maturation antigen (BCMA), wherein
- (a) the antibodies or binding fragments comprise a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:19;
- and
- (b) less than 10% of the antibodies in the composition are fucosylated.
A composition comprising a plurality of immunoglobulin G1 (IgG1) antibodies that bind to human B-cell maturation antigen (BCMA), wherein
- (a) the antibodies comprise a mature heavy chain variable region and a mature light chain variable region, wherein the mature heavy chain variable region comprises complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 60, 61 and 62, and the mature light chain variable region comprises CDRs comprising the amino acid sequences of SEQ ID NOs:90, 91 and 92;
- and
- (b) less than 5% of the antibodies in the composition are fucosylated.
A composition comprising a plurality of immunoglobulin G1 (IgG1) antibodies that bind to human B-cell maturation antigen (BCMA), wherein
- (a) the antibodies comprise
- (i) a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:19;
- and
- (ii) a heavy chain constant region comprising the amino acid sequence of SEQ ID NO:5, and a light chain constant region comprising the amino acid sequence of SEQ ID NO:3;
- and
- (b) less than 5% of the antibodies in the composition are fucosylated.
A composition comprising a plurality of monoclonal antibodies with reduced fucosylation that bind to human B-cell maturation antigen (BCMA), wherein
- (a) the antibodies in the composition are produced by a process comprising culturing a host cell that express the antibodies in a culture medium suitable to produce antibodies with reduced fucosylation, and isolating the antibodies with reduced fucosylation from the culture medium;
- and
- (b) the antibodies in the composition comprise a mature heavy chain variable region and a mature light chain variable region, wherein the mature heavy chain variable region comprises complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 60, 61 and 62, and the mature light chain variable region comprises CDRs comprising the amino acid sequences of SEQ ID NOs:90, 91 and 92.
A composition comprising a plurality of monoclonal antibodies with reduced fucosylation that bind to human B-cell maturation antigen (BCMA), wherein
- (a) the antibodies in the composition are produced by a process comprising culturing a host cell that expresses the antibodies in a culture medium suitable to produce antibodies with reduced fucosylation, and isolating the antibodies with reduced fucosylation from the culture medium;
- and
- (b) the antibodies in the composition comprise a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:19.
A composition comprising a plurality of monoclonal, immunoglobulin G1 (IgG1) antibodies that bind to human B-cell maturation antigen (BCMA), wherein:
- (a) the antibodies in composition are produced by process comprising culturing a host cell that expresses the antibodies in a culture medium containing 2-fluorofucose, and isolating the antibodies from the culture medium;
- (b) antibodies in the composition comprise a mature heavy chain variable region and a mature light chain variable region, wherein the mature heavy chain variable region comprises complementarity determining regions (CDRs) comprising the amino acid sequences of SEQ ID NOs:
- 60, 61 and 62, and the mature light chain variable region comprises CDRs comprising the amino acid sequences of SEQ ID NOs:90, 91 and 92;
- and
- (c) less than 5% of the antibodies in the composition are fucosylated.
A composition comprising a plurality of monoclonal, immunoglobulin G1 (IgG1) antibodies that bind to human B-cell maturation antigen (BCMA), wherein:
- (a) the antibodies in composition are produced by process comprising culturing a host cell that expresses the antibodies in a culture medium containing 2-fluorofucose, and isolating the antibodies from the culture medium;
- (b) the antibodies in the composition comprise a mature heavy chain variable region comprising the amino acid sequence of SEQ ID NO:13, and a mature light chain variable region comprising the amino acid sequence of SEQ ID NO:19;
- and
- (c) less than 5% of the antibodies in the composition are fucosylated.
Dependencies are inferred from the claim text.